Company Overview

Development Stage

About the Company

信立泰(苏州)药业有限公司成立于2010年9月,注册资金8070.92万元,主要从事生物技术药物产业化开发,为上市公司深圳信立泰药业股份有限公司(股票代码002294)控股公司(信立泰药业2018年营业收入达46.52亿元,市值超过350亿元,位居国内医药工业企业前茅,先后荣膺“中国医药上市公司竞争力20强”、“中国中小板上市公司价值10强”)。
信立泰(苏州)药业建有苏州市重组蛋白药物工程技术研究中心,现有NDA产品1项,临床Ⅱ期项目2项,SFDA临床审评中项目1项,以及若干储备项目,产品涉及肿瘤、组织修复、消化系统疾病、自身免疫疾病等领域,涵盖重组蛋白、重组抗体等。项目相关专利13项,授权专利9项。
苏州公司现有员工150人,本硕学历人员86%,涵盖生物、化学、医学专业。团队被授予2010年度太仓市创新创*人才、2011年度姑苏*人才、2011年度江苏省“双创”人才,承担2013年江苏省成果转化专项资金项目,入选2015年江苏省“双创计划”团队。
信立泰(苏州)药业在太仓生物医药产业园投资约3亿元建设符合GMP要求的生物医药产业化基地,基地占地面积60亩,车间建筑面积13000m2,包括西林瓶水针/冻干粉针生产线、卡式瓶生产线,产能规模冻干粉针年产2000万支、重组蛋白100kg。原液车间、制剂车间2015年完成建设及设备负载运行,2016年取得《药品生产许可证》。
公司提供五险一金、带薪年假、职业培训、年度体检、年度旅游、文化体育娱乐活动及生日、结婚等各大礼金,免费提供一日三餐和舒适的住宿环境,坚持“以奋斗者为本”,建立激励薪酬体系,用适应和匹配的薪酬留住人才,提倡为卓越加薪。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Recruitment Overview / Current Status (2 open positions)

Manage
Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Campus Recruitment & Advanced Degree Talent Demand
Interns 1
Note: How fast is hiring at 信立泰(苏州)药业有限公司 growing? 2026: 6 openings, 2025: 6 openings, 2023: 1 openings, 2022: 22 openings, 2021: 45 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

— What Are the Salaries Like? (10 records)

Manage
salary range: 6K - 50K, 70% of roles pay ¥6-10K
Note: salary statistics are based on 10 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 信立泰(苏州)药业有限公司?70% of positions earn 6-10K, Undergraduate salary: ¥。生物/制药/化工/环保类 average salary ¥15.3K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Related Industry Tags

Job Category

  • 生物/制药/化工/环保类
    50% of total 50%
  • 工厂生产类
    16.7% of total 16.7%
  • 技工类
    16.7% of total 16.7%
  • 其他(研发和技术类)
    8.3% of total 8.3%

Education

  • 大专
    50% of total 50%
  • 高中
    16.7% of total 16.7%
  • 本科
    16.7% of total 16.7%
  • 不限
    16.7% of total 16.7%

Experience

  • 不限
    100% of total 100%
View Detailed Analysis

What does 信立泰(苏州)药业有限公司 require? Who is 信立泰(苏州)药业有限公司 hiring? recruitment: 生物/制药/化工/环保类占比最多占50%,其次是工厂生产类占16.7%. What education can get in at ? 大专占比最多占50%,其次是高中占16.7%. Work experience required at ? 不限占比最多占100%. Where are the job locations at ? 苏州占比最多占100%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 21,243.0446万(元)
Legal Representative: 邸子渊
Date Established:
Credit Code: 9132058556290997XU
Registered Address: 太仓市沙溪镇梦溪路1号

People who follow this company also follow

Competitors (Similar Companies)

“High-end prescription drugs, interventional medical devices”
“Research and development and industrialization of monoclonal antibody ”
新材料 阻燃剂 环保材料 橡胶
房地产开发 实业投资 典当 办公空间
“β-内酰胺酶抑制剂原料药生产基地,碳青霉烯类药物的主要供应商之一”
“让原创药禧济天下”
胶粘剂 医药中间体 催化剂 树脂
“A renowned enterprise in China's liver disease and anti-tumor fields”
“中国葡萄酒产区龙头企业”
医药 医药中间体 原料药 中间体
工业机器人 工业物联 工业物联网 智能机器人
“Promoting human health”
生命科学 生物信息 生物制药 干细胞
“Machine Vision and Intelligent Manufacturing”
“China's first national technology enterprise to independently research”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates